Novel Fixed-Dose Combination Tablet Shows Promise in Treating Canine Myxomatous Mitral Valve Disease

Strategic Insights -

In a groundbreaking study published in Frontiers in Veterinary Science, researchers from VIP Animal Medical Center in Seoul, South Korea, have discovered a novel fixed-dose combination tablet, Sentorphil ForteGold, to be a clinically effective and safer alternative to traditional compounded powdered medications for managing myxomatous mitral valve disease (MMVD) in dogs. The randomized, double-blind clinical trial involved 60 client-owned dogs with stage C MMVD, who were assigned to receive either Sentorphil ForteGold or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone.

Key Takeaways:

  • Sentorphil ForteGold, a novel fixed-dose combination tablet, showed significant improvements in clinical signs, including exercise intolerance, appetite, respiratory effort, and coughing, in dogs with MMVD.
  • The ForteGold group demonstrated earlier and more sustained responses compared to the compounded powdered mixture group.
  • Blood chemistry and electrolyte levels remained within normal ranges, indicating a favorable safety profile for Sentorphil ForteGold.
  • Radiographic assessments revealed a gradual decrease in vertebral heart score and normalization of lung fields by Day 56 in both groups.
  • Echocardiographic parameters improved significantly, with the ForteGold group demonstrating earlier enhancements.
  • NT-proBNP levels decreased in both groups, with a more pronounced reduction in the ForteGold group.
  • The study suggests that Sentorphil ForteGold offers a safer and more effective alternative to traditional treatments for MMVD in dogs.
  • Further studies with larger populations and extended follow-up periods are warranted to confirm these findings.

Statistics:

  • 60 client-owned dogs with stage C MMVD were enrolled in the study.
  • 30 dogs were assigned to receive Sentorphil ForteGold, and 30 dogs received a compounded powdered mixture.
  • Clinical signs improved significantly in both groups, with the ForteGold group demonstrating earlier and more sustained responses.
  • Blood chemistry and electrolyte levels remained within normal ranges in both groups, indicating a favorable safety profile.
  • Radiographic assessments revealed a gradual decrease in vertebral heart score and normalization of lung fields by Day 56 in both groups.
  • Echocardiographic parameters improved significantly, with the ForteGold group demonstrating earlier enhancements.
  • NT-proBNP levels decreased by 23% in the ForteGold group and 15% in the compounded powdered mixture group.

Sources:

  • Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study. Frontiers in Veterinary Science, 2025;12:1622383.
  • VIP Animal Medical Center, Seoul, South Korea.
  • Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.